Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(43%)
Results Posted
50%(1 trials)
Terminated
1(14%)

Phase Distribution

Ph early_phase_1
1
14%
Ph not_applicable
3
43%
Ph phase_1
1
14%
Ph phase_3
1
14%
Ph phase_4
1
14%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
1(14.3%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
1(14.3%)
N/ANon-phased studies
3(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Completed(2)
Terminated(1)

Detailed Status

Recruiting2
Completed2
Active, not recruiting1
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (14.3%)
Phase 11 (14.3%)
Phase 31 (14.3%)
Phase 41 (14.3%)
N/A3 (42.9%)

Trials by Status

active_not_recruiting114%
recruiting229%
terminated114%
not_yet_recruiting114%
completed229%

Recent Activity

Clinical Trials (7)

Drug Details

Intervention Type
DRUG
Total Trials
7